Attralus Raises $116m To Advance Amyloidosis-Clearing Pipeline
Executive Summary
The company intends to use the series B cash to bring the first of its pan-amyloid removal (PAR) therapies into the clinic, while also advancing a diagnostic tool for systemic amyloidosis.